Fanny Monmousseau

ORCID: 0000-0002-3673-1724
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical Economics and Policy
  • Microscopic Colitis
  • Kidney Stones and Urolithiasis Treatments
  • Inflammatory Bowel Disease
  • Economic and Environmental Valuation
  • Healthcare Systems and Practices
  • French Urban and Social Studies
  • Medication Adherence and Compliance
  • Healthcare Policy and Management
  • Autoimmune and Inflammatory Disorders Research
  • Pediatric Urology and Nephrology Studies
  • Pharmacogenetics and Drug Metabolism
  • Systemic Lupus Erythematosus Research
  • Cancer Treatment and Pharmacology
  • Global Healthcare and Medical Tourism
  • Pharmaceutical industry and healthcare
  • Statistical Methods in Clinical Trials
  • Eosinophilic Esophagitis
  • Economic and Financial Impacts of Cancer
  • Bipolar Disorder and Treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Organ Transplantation Techniques and Outcomes
  • Patient-Provider Communication in Healthcare
  • Clinical practice guidelines implementation

Centre Hospitalier Universitaire de Tours
2016-2025

Université de Tours
2016-2023

Université Paris Cité
2009

École Supérieure des Sciences Économiques et Commerciales
2008

Université de Pau et des Pays de l'Adour
2008

Bevacizumab shows inter-individual pharmacokinetic variability, with an exposure-response relationship in metastatic colorectal cancer (mCRC) patients. This study explores whether a double dose of bevacizumab, compared to standard dose, increases efficacy mCRC patients treated bevacizumab-based chemotherapy as first-line therapy and who have low initial trough concentration bevacizumab. PHARBEVACOL is multicenter, randomized, double-blind, two-parallel group trial. All will receive bi-weekly...

10.1016/j.dld.2025.02.002 article EN cc-by Digestive and Liver Disease 2025-03-01

It remains uncertain whether the most appropriate management for women with an unfavourable cervix after 24 hours of cervical ripening is repeating procedure or proceeding directly to induction by oxytocin. No adequately powered trial has compared these strategies. We hypothesise that labour oxytocin among who have just undergone ineffective first not associated a higher risk caesarean delivery than repeated prostaglandins.

10.1136/bmjopen-2021-058282 article EN cc-by-nc BMJ Open 2023-04-01

Endoscopic procedures such as ureteroscopy (URS) have seen a recent increase in single-use devices. Despite all the advantages provided by disposable ureteroscopes (sURSs), their cost effectiveness remains questionable, leading most teams to use hybrid strategy combining reusable (rURS) and Our study aimed create an economic model that estimated cut-off value of rURS needed support profitability (HS) for ureteroscopy. We used budget impact analysis (BIA) financial HS compared 100% sURS use....

10.3390/jcm10122593 article EN Journal of Clinical Medicine 2021-06-11

Cet article analyse les propriétés incitatives de la loi SRU, promulguée en France décembre 2000, dont l'une des finalités est d'accroître l'offre logements sociaux dans communes qui sont relativement dépourvues. Il apporte notamment éclairages sur raisons pour lesquelles se très inégalement conformées aux objectifs loi. Grâce à un modèle principal-agent, nous montrons que l'effort réalisé par élus locaux dépend arbitrages économiques et politiques qu'ils opèrent. Le théorique a également...

10.4000/economiepublique.6442 article FR Économie publique/Public economics 2008-02-01

Anti-TNFs have been shown to significantly improve the health-related quality of life (HRQoL) in Crohn's disease (CD) patients. The purpose this study was investigate what extend patients' preferences for these intravenous (IV) and subcutaneous (SC) treatments differ based on respondents' life. An online discrete choice experiment (DCE) conducted understand patient trade-offs treatment choice.Fifty-seven anti-TNF naïve patients were asked choose between two different scenarios, considering...

10.1080/00365521.2022.2085057 article EN Scandinavian Journal of Gastroenterology 2022-06-18

Les biomédicaments constituent une part croissante des innovations thérapeutiques. En raison de leurs prix souvent très élevés, les dernières générations sont inscrites sur la liste en sus prestations d’hospitalisation façon à rendre l’accès l’innovation équitable. L’objectif cet article est d’étudier contribution l’évolution dépense molécules onéreuses, l’échelle région Centre-Val Loire, entre 2008 et 2013. L’utilisation d’indices statistiques nous permet dissocier ce qui relève d’un...

10.3917/jgem.181.0035 article FR Journal de gestion et d économie médicales 2018-05-23

Abstract Background Nowadays, the main challenge of transplantation is improvement long-term care, aiming at reducing treatment-related complications and decreasing rejection rates. Patients’ adherence to both treatment hygienic-dietary measures mandatory achieve these objectives. Adherence immunosuppressive drugs estimated be only 70%. We hypothesized that implementation a personalized pharmaceutical plan (PPP) would increase therefore graft survival. Methods/design This study stepped-wedge...

10.1186/s13063-021-05749-w article EN cc-by Trials 2021-11-08

You have accessJournal of UrologyStone Disease: Epidemiology & Evaluation I (MP08)1 Apr 2019MP08-17 BUDGET IMPACT ANALYSIS TO SUPPORT THE DECISION BETWEEN REPLACING REUSABLE FLEXIBLE URETEROSCOPES BY SINGLE USE DEVICES AND ADOPTING A HYBRID STRATEGY FOR UROLITHIASIS TREATMENT Benjamin Pradere, Dubnitskiy-Robin Sophie, benjamin Faivre D'Arcier, Sophie Watt, Tanguy Le Fol, Eric Rusch, Fanny Monmousseau, and Sylvie Brunet-Houdard PradereBenjamin Pradere More articles by this author ,...

10.1097/01.ju.0000555121.08155.a0 article EN The Journal of Urology 2019-04-01
S. G. Steadman Benjamin K. Canales Danilo Bottero Cristiana Fanciullo Guido Bonomo and 95 more Matteo Ferro Ottavio De Cobelli Ming-Chun Chan Jia-Lun Kwok Sharon Yeo Lam Chong Andrew J. Vickers Samson W. Fine Nicole Wake Jeffrey Nussbaum Marie I. Elias Christine Nikas Marc A. Bjurlin Alireza Aminsharifi Jihad Kaouk Ajay Gopalakrishna Raevti Bole Roy Lipworth Masaya Jimbo Sevann Helo Tobias Köhler Matthew Ziegelmann Yasuyuki Miyauchi Homare Okazoe Makiko Tamaki Takako Kakehi Hirohisa Ichikawa Yukako Arakawa Yoshihiro Mori Fumikazu Koui Mikio Sugimoto Yoshiyuki Kakehi Aaron Lentz Dayron Rodr Iguez Jason Chandrapal Leah Davis Ahmed Ghazi Martin Gross Ricardo Munarriz Alexander P. Kenigsberg Roger K. Khouri Amy Kuprasertkul Daniel Wong Vishnu Ganesan Gary E. Lemack Katherine E. Fero James Weinberger Steven E. Lerman Jonathan Bergman Sophie Dubnitskiy-Robin Benjamin Prad B. Faivre d’Arcier Sophie Watt Tanguy Le Fol Franck Bruy Ere Emmanuel Rüsch Fanny Monmousseau Sol Ene Brunet-Houdard Parth Patel Chirag Doshi Alex Belshoff Marc Nelson Patrick Sweigert Corinne Bunn Sujay Kulshrestha Marshall S. Baker Michael Woods Gopal N. Gupta Charles J. Paul Thomas S. Gruca Paul G. Morrison George Ghareeb Sang Kim Bradley Erickson Infertility Joshua A. Halpern Katelyn Zumpf Mary Kate Keeter Alexander J. Tatem Barbara E. Kahn Nelson Bennett Leah J. Welty Robert E. Brannigan Reza Mehrazin Eric Bortnick Rollin Say Jared S. Winoker Siobhan Telfer Mark W. Ball Arnaldo N. S. Silva Fanourios Georgiades Michael Bath Sarah A. Hosgood Michael L. Nicholson Louis Lenfant Clark A. Wilson

10.1016/s0090-4295(20)30894-3 article EN Urology 2020-08-28

Background and aims In Crohn’s disease (CD), a composite therapeutic target was recently recommended, including both objective measurement (endoscopic remission) Patient-Reported Outcomes (resolution of abdominal pain normalization bowel function). All dimensions health-related quality life (HRQoL) are impacted: not only symptoms but also systemic symptoms, emotional wellbeing social function. Thus, understanding the predictors each HRQoL dimension would improve patient management. However,...

10.1080/00365521.2021.2025419 article EN Scandinavian Journal of Gastroenterology 2022-02-21
Coming Soon ...